DNV GL and Renji Hospital have announced the renewal of their partnership, marking the seventh year of their collaboration. This long-standing commitment reflects their shared goal of improving the quality of healthcare. In October 2020, VeChain (VET) joined forces with DNV GL and Renji Hospital, which is affiliated with the Shanghai Jiao Tong University School of Medicine, to launch the world’s first Intelligent Tumor Treatment Center powered by blockchain technology. This center, powered by the VeChain Toolchain, aims to provide a transparent, efficient, and traceable medical management solution.
The partnership sought to leverage the benefits of the VeChain blockchain and the professional services offered by DNV GL. The primary objective was to empower patients with control over their medical records. Additionally, both internal and external research institutions could utilize authorized data to enhance clinical research, while regulatory agencies could conduct compliance checks on medical institutions and evaluate their creditworthiness.
George Kang, Senior Vice President of DNV GL Group, expressed his thoughts on the matter, stating that the launch of the Intelligent Tumor Treatment Center is intended to enhance the integrated development of Renji Hospital. He also mentioned that Renji Hospital plans to introduce more blockchain-powered use cases and projects in the future, which will be disclosed gradually in collaboration with their partners.
Renji Hospital and DNV GL have now renewed their partnership, further solidifying their relationship. This renewal highlights their ongoing commitment to enhancing international medical quality certification. Notably, Renji Hospital began the process of certifying its international outpatient program to DNV’s quality standards in January 2017. They successfully passed the initial evaluation in April 2018, enabling the international outpatient clinic to improve its service quality.
George Kang emphasized that the collaboration between DNV GL and Renji Hospital is focused on improving quality. Through independent and objective medical evaluation methods, DNV GL aims to provide additional services to Renji Hospital, further enhancing its service quality and medical experience.
This partnership aligns with the Chinese government’s 14th Five-Year (2021-2025) Plan for Economic and Social Development. The National Health Commission has emphasized the importance of blockchain technology as a crucial innovation for integration into the medical and health industry.
VeChain, together with DNV GL, has already demonstrated success in the medical sector with its self-developed one-stop data BaaS platform, VeChain ToolChain. They have implemented blockchain-powered solutions such as the Clinical Trial Traceability Platform for Bayer China and the blockchain-enabled medical data management platform called The E-NewHealthLife for the Mediterranean Hospital of Cyprus. In response to the digital transformation demands brought on by COVID-19, VeChain and DNV GL are actively seeking opportunities to develop high-efficiency and cost-effective digital solutions for the medical industry.
